Metronidazole / Nystatin (Flagystatin)
Antiprotozoal/antibacterial and antifungal combination (trichomonacide-moniliacide)
Metronidazole / Nystatin (Flagystatin)
Forms and strengths
Form: SuppositoryStrength: 500 mg metronidazole and 100, 000 IU nystatin per ovule
References
Indication
- Flagystatin is used to treat mixed vaginal infections caused by Trichomonas vaginalis and Candida albicans occurring together.
- It should only be used when a mixed infection has been confirmed or is strongly suspected, to help limit the development of drug-resistant organisms.
Pregnancy
- Metronidazole crosses the placenta, and its effects on human fetal development are not fully known, so its use should generally be avoided in pregnancy, particularly during the first trimester.
- Reliable animal safety data for nystatin in pregnancy are not available, so it should also be avoided unless the benefit to the mother outweighs the potential risk to the fetus.
- The vaginal applicator supplied with Flagystatin should not be used after the seventh month of pregnancy.
Breastfeeding
- Metronidazole passes into breast milk, so exposure to the drug through breastfeeding should be avoided during treatment.
- It is not known whether nystatin passes into breast milk.
Geriatrics
- No data are available on the use of Flagystatin in geriatric patients, so Health Canada has not authorized a specific geriatric indication.
Pediatrics
- No data are available on the use of Flagystatin in patients under 18 years of age, so Health Canada has not authorized a pediatric indication.
Dosage & Administration
- The usual dose is one vaginal ovule inserted deep into the vagina once daily, at bedtime, for 10 consecutive days.
- If the infection is not cured after 10 days, a second 10-day course may be given.
- If Trichomonas vaginalis is not completely eliminated after two courses, oral metronidazole may be added to the treatment.
- The applicator provided with Flagystatin should not be used after the seventh month of pregnancy.
- If a dose is missed, it should be skipped and the regular schedule resumed the next day; a double dose should never be inserted to make up for a missed one.
- Patients with severe liver disease may need a lower-than-usual dose because metronidazole is metabolized slowly and can build up in the body.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- No case of accidental massive ingestion of Flagystatin itself has been reported.
- Single oral metronidazole doses as high as 12 grams have been reported in accidental and intentional overdoses, causing vomiting, unsteady movements (ataxia), and mild disorientation.
- Very large oral doses of nystatin can cause gastrointestinal symptoms such as nausea, vomiting, and diarrhea.
- There is no specific antidote for metronidazole or nystatin overdose; activated charcoal may help remove unabsorbed drug, and general supportive care is recommended.
Common side effects
- A burning or grainy sensation in the vagina may occur.
- Darker-than-usual urine may occur, caused by a metronidazole breakdown product; this is not harmful.
- Constipation may occur.
- Dry mouth may occur.
- A bitter or metallic taste may occur.
- Indigestion or upset stomach may occur.
- Loss of appetite may occur.
- Nausea or vomiting may occur.
- Headache may occur.
- Trouble sleeping may occur.
- A coated tongue may occur.
- Fatigue may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Severe skin reactions, including Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalized exanthematous pustulosis, and drug reaction with eosinophilia and systemic symptoms, have been reported and require immediate discontinuation.
- Severe liver toxicity or acute liver failure, sometimes fatal, has been reported with very rapid onset in patients with Cockayne syndrome; liver function should be monitored closely before, during, and after treatment in this group.
- Increased liver enzymes, cholestatic or mixed hepatitis, and liver injury with jaundice have been reported.
- Cases of liver failure requiring transplant have occurred when metronidazole was combined with other antibiotics.
- Seizures and peripheral or central nervous system toxicity, including numbness, tingling, unsteady movement, and dizziness, may occur.
- Posterior reversible encephalopathy syndrome, a brain-swelling condition causing headache, confusion, seizures, and visual changes, has been reported and requires immediate discontinuation.
- Suicidal thoughts, with or without depression, and other psychiatric symptoms such as confusion or hallucinations have been reported.
- Severe allergic reactions, including anaphylaxis and angioedema, may occur.
- A drop in white blood cells or platelets may occur, increasing the risk of infection or bleeding.
- Pseudomembranous colitis, a severe form of antibiotic-associated bowel inflammation, has been reported.
- QT interval prolongation, which can cause a dangerous irregular heartbeat, has been reported, particularly when combined with other QT-prolonging drugs.
- Optic neuropathy or neuritis, causing vision changes, has been reported rarely.
- Meningitis has been reported rarely.
- Seek urgent medical attention for yellowing of the skin or eyes, severe skin peeling or blistering, seizures, thoughts of self-harm, or signs of a severe allergic reaction.
Use with caution
- Use with caution in patients with a history of active neurological disease, since metronidazole can worsen neurological symptoms.
- Use with caution in patients with a history of blood dyscrasia, since metronidazole treatment can affect blood cell counts.
- Use with caution in patients with hypothyroidism or hypoadrenalism.
- Use with caution in patients with liver disease or a history of liver problems related to previous metronidazole use.
- Use with caution in patients with Cockayne syndrome, who require close liver function monitoring throughout treatment.
- Use with caution in patients with a history of mental health problems, since metronidazole has been linked to confusion, hallucinations, and suicidal ideation.
- Avoid driving or operating machinery if confusion, dizziness, vertigo, hallucinations, seizures, or vision problems occur during treatment.
- Use with caution regarding fertility devices, since the fatty base of the ovule can reduce the effectiveness of condoms and diaphragms.
Contraindications
- Contraindicated in patients with known hypersensitivity to metronidazole, nystatin, imidazole antifungals, or any component of the ovule.
Drug interactions
- Alcohol and alcohol-containing products should be avoided during treatment and for at least one day afterward because of a possible disulfiram-like reaction causing flushing, vomiting, and a fast heartbeat.
- Warfarin and other oral anticoagulants may have their effect increased, raising the risk of bleeding; more frequent monitoring is advised.
- Busulfan levels may increase, raising the risk of severe busulfan toxicity.
- Cyclosporine levels may increase, requiring closer monitoring of cyclosporine and creatinine levels.
- Disulfiram combined with metronidazole has been linked to psychotic reactions.
- Drugs that prolong the QT interval may increase the risk of a dangerous heart rhythm change when combined with metronidazole.
- 5-Fluorouracil clearance may be reduced, increasing its toxicity.
- Lithium levels may increase, requiring monitoring of lithium, creatinine, and electrolyte levels.
- Phenytoin and phenobarbital can increase the elimination of metronidazole, lowering its blood levels, while phenytoin levels themselves may rise during concurrent use.
- Vecuronium's muscle-relaxant effect may be slightly increased when combined with metronidazole.
Food interactions
- Flagystatin is inserted vaginally rather than swallowed, so there is no food interaction or meal-timing requirement for this product.
Time of administration
- Insert one ovule deep into the vagina at bedtime each day for the full course, regardless of meal timing, since this is a vaginally administered product rather than one taken by mouth.
Storage
- Store Flagystatin ovules at room temperature, between 15°C and 25°C.
- Protect from light.
Patient take-away
- Flagystatin treats two vaginal infections at once by combining an antiprotozoal/antibacterial ingredient with an antifungal ingredient.
- Complete the full course even if symptoms improve early, to reduce the chance of the infection coming back or becoming resistant.
- Avoid alcohol during treatment and for one day afterward to prevent an unpleasant reaction.
- Watch for signs of severe skin reactions or liver problems, such as yellowing skin, severe rash, or unusual tiredness, and seek care right away if these occur.